It was a pleasure to discuss with Prof. Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany) the post-hoc analysis from sub-populations of the phase 3 SPIRIT-1 (NCT01695239) and SPIRIT-2 (NCT02349295) trials aimed at determining the efficacy of ixekizumab in reducing axial symptoms and improving quality of life in patients with PsA and symptoms of axial involvement.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement’ (ABSTRACT NUMBER: 1347) was presented at the ACR Convergence, 5-9 November.
Questions
- What are the manifestations of axial involvement in psoriatic arthritis and what are their prevalence? (0:13)
- Could you tell us a little about the efficacy of ixekizumab in psoriatic arthritis and the post-hoc analysis you conducted? (1:02)
- What were the findings of the analysis? (2:09)
Disclosures: Prof Poddubnyy has received research support from AbbVie, Eli Lilly, MSD, Novartis, and Pfizer; consulting fees from AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB; and speaker fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
